Delaware
|
000-54402
|
91-1835664
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File No.)
|
(IRS Employer Identification Number)
|
40 Marcus Drive, Melville, New York
|
11747
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
____
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
____
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
____
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
____
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
1.
|
Election of Class I Directors:
|
|
Number of Shares
|
||
|
For
|
Withheld
|
Broker Non-Votes
|
Robert B. Catell
|
3,919,059
|
16,536
|
1,038,148
|
Charles S. Ryan
|
3,920,060
|
15,535
|
1,038,148
|
2.
|
Approval of an amendment to the Company's Certificate of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 30,000,000 to 75,000,000:
|
For
|
4,869,597
|
Against
|
85,769
|
Abstentions
|
18,377
|
Broker Non-Votes
|
0
|
3.
|
Approval of an amendment to the Company's Certificate of Incorporation to increase the number of shares of preferred stock authorized to be issued by the Company from 5,000,000 to 20,000,000:
|
For
|
3,897,760
|
Against
|
37,834
|
Abstentions
|
1
|
Broker Non-Votes
|
1,038,148
|
4.
|
Approval of an amendment to the Company's 2010 Equity Participation Plan (the "
Plan
") to increase the number of shares of common stock authorized to be issued pursuant to the Plan from 4,250,000 to 10,000,000:
|
For
|
3,898,760
|
Against
|
36,834
|
Abstentions
|
1
|
Broker Non-Votes
|
1,038,148
|
5.
|
Ratification of the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018:
|
For
|
4,972,592
|
Against
|
146
|
Abstentions
|
1,005
|
Broker Non-Votes
|
0
|
Item 9.01
|
Financial Statements and Exhibits
.
|
BIORESTORATIVE THERAPIES, INC.
|
|||
Dated: August 24, 2018
|
By:
|
/s/ Mark Weinreb | |
Mark Weinreb | |||
Chief Executive Officer
|
|||
BioRestorative Therapies, Inc. | |||
|
By:
|
/s/ Mark Weinreb | |
Mark Weinreb | |||
Chief Executive Officer | |||